"The chemical name is fluoroestradiol F 18 is [18F]16α-fluoro-3,17β-diol-estratriene-1,3,5."
"Fluorine-18 fluoroestradiol (F-18 FES) is a PET radiotracer that combines the positron-emitting fluorine-18 radionuclide with a synthetic oestrogen analogue."
"F-18 is produced using a cyclotron. This agent is then radiolabeled with the oestrogen analogue. The US Food and Drug Administration approved the radiotracer F-18 FES in May 2020. In the United States, it is manufactured with the brand name Cerianna (GE Healthcare Inc)."
"F-18 is produced using a cyclotron. This agent is then radiolabeled with the oestrogen analogue. The US Food and Drug Administration approved the radiotracer F-18 FES in May 2020. In the United States, it is manufactured with the brand name Cerianna (GE Healthcare Inc)."
"F-18 is produced using a cyclotron. This agent is then radiolabeled with the oestrogen analogue. The US Food and Drug Administration approved the radiotracer F-18 FES in May 2020. In the United States, it is manufactured with the brand name Cerianna (GE Healthcare Inc)."
"Current recommendations require a washout period for drugs that bind to the oestrogen receptor before FES PET imaging: 11 days for elacestrant, 8 weeks for tamoxifen, and 28 weeks for fulvestrant. No washout time is required for aromatase inhibitors as they decrease oestrogen production but do not block the oestrogen receptor."
"The effect of F18 FES on breastfeeding has not been studied. The manufacturer recommends not breastfeeding for at least 4 hours after administration."
"Unlike FDG, FES does not localise to infectious, inflammatory, or other reactive processes. An exception is radiation pneumonitis, which may demonstrate moderate activity."
"F-18 FES is used to identify tumour that expresses the oestrogen receptor (ER+), a finding that can guide hormonal therapy, especially for breast cancer. This can be complicated as breast cancer hormone receptor expression can be heterogenous throughout the body, in different tumours, and at different times in the same patient."
"F-18 FES is used to identify tumour that expresses the oestrogen receptor (ER+), a finding that can guide hormonal therapy, especially for breast cancer. This can be complicated as breast cancer hormone receptor expression can be heterogenous throughout the body, in different tumours, and at different times in the same patient."
"F-18 FES has been approved for use to identify target lesions for confirmatory biopsy, assessment of biopsy-proven ER-positive disease, and clarification of FDG-avid findings. It is especially useful for the evaluation of invasive lobular carcinoma, for which fluorodeoxyglucose (FDG) has a lower sensitivity."
"F-18 FES has been approved for use to identify target lesions for confirmatory biopsy, assessment of biopsy-proven ER-positive disease, and clarification of FDG-avid findings. It is especially useful for the evaluation of invasive lobular carcinoma, for which fluorodeoxyglucose (FDG) has a lower sensitivity."
"Additional uses currently under study include predicting response to selective therapy and local therapy (cryoablation), assessing effectiveness of hormonal blockade, initial staging of ER+ breast cancer, and clinical use for other oestrogen receptor-expressing conditions, such as ovarian or uterine tumours."
"F-18 FES is used to identify tumour that expresses the oestrogen receptor (ER+), a finding that can guide hormonal therapy, especially for breast cancer. This can be complicated as breast cancer hormone receptor expression can be heterogenous throughout the body, in different tumours, and at different times in the same patient."
Expected headings
"Structure"
"Production"
"Pharmacokinetics"
"Administration guidelines"
"Biodistribution"
"Clinical uses"
"Additional uses currently under study include predicting response to selective therapy and local therapy (cryoablation), assessing effectiveness of hormonal blockade, initial staging of ER+ breast cancer, and clinical use for other oestrogen receptor-expressing conditions, such as ovarian or uterine tumours."